Oncolytic virotherapy

Keyphrases

Publications

volume 7, 2018

Matthew B Phillips, Johnasha D Stuart, Roxana M Rodríguez Stewart, Jameson Tl Berry, Bernardo A Mainou, Karl W Boehme
Current understanding of reovirus oncolysis mechanisms. Oncolytic virotherapy 7 (2018)
Tien V Nguyen, Catherine M Crosby, Gregory J Heller, Zachary I Mendel, Mary E Barry, Michael A Barry
Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer. Oncolytic virotherapy 7 (2018)
Jonathan G Pol, Matthew J Atherton, Byram W Bridle, Kyle B Stephenson, Fabrice Le Boeuf, Jeff L Hummel, Chantal G Martin, Julia Pomoransky, Caroline J Breitbach, Jean-Simon Diallo, David F Stojdl, John C Bell, Yonghong Wan, Brian D Lichty
Development and applications of oncolytic Maraba virus vaccines. Oncolytic virotherapy 7 (2018)
Raquel Yokoda, Bolni M Nagalo, Mansi Arora, Jan B Egan, James M Bogenberger, Thomas T DeLeon, Yumei Zhou, Daniel H Ahn, Mitesh J Borad
Oncolytic virotherapy in upper gastrointestinal tract cancers. Oncolytic virotherapy 7 (2018)
Linus D Kloker, Can Yurttas, Ulrich M Lauer
Three-dimensional tumor cell cultures employed in virotherapy research. Oncolytic virotherapy 7 (2018)
Sareh Zhand, Seyed Masoud Hosseini, Alijan Tabarraei, Mohsen Saeidi, Marie Saghaeian Jazi, Mohamad Reza Kalani, Abdolvahab Moradi
Oral poliovirus vaccine-induced programmed cell death involves both intrinsic and extrinsic pathways in human colorectal cancer cells. Oncolytic virotherapy 7 (2018)
Chase Burton, Arabinda Das, Daniel McDonald, William A Vandergrift, Sunil J Patel, David Cachia, Eric Bartee
Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiforme. Oncolytic virotherapy 7 (2018)
Adrian Pelin, Jiahu Wang, John Bell, Fabrice Le Boeuf
The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic viruses. Oncolytic virotherapy 7 (2018)
Chun-Yu Chen, Brian Hutzen, Mary F Wedekind, Timothy P Cripe
Oncolytic virus and PD-1/PD-L1 blockade combination therapy. Oncolytic virotherapy 7 (2018)
Chun Xu, Annika Verena Goß, Carmen Dorneburg, Klaus-Michael Debatin, Jiwu Wei, Christian Beltinger
Proof-of-principle that a decoy virus protects oncolytic measles virus against neutralizing antibodies. Oncolytic virotherapy 7 (2018)
Eric Bartee
Potential of oncolytic viruses in the treatment of multiple myeloma. Oncolytic virotherapy 7 (2018)

volume 6, 2017

Faris Farassati
Editorial announcing PubMed indexing of Oncolytic Virotherapy. Oncolytic virotherapy 6 (2017)
Teridah Ernala Ginting, Jeremiah Suryatenggara, Salomo Christian, George Mathew
Proinflammatory response induced by Newcastle disease virus in tumor and normal cells. Oncolytic virotherapy 6 (2017)
Hani M Babiker, Irbaz Bin Riaz, Muhammad Husnain, Mitesh J Borad
Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. Oncolytic virotherapy 6 (2017)
Yoshihiro Hotta, Hideki Kasuya, Itzel Bustos, Yoshinori Naoe, Toru Ichinose, Maki Tanaka, Yasuhiro Kodera
Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity. Oncolytic virotherapy 6 (2017)
Raquel Yokoda, Bolni M Nagalo, Brent Vernon, Rahmi Oklu, Hassan Albadawi, Thomas T DeLeon, Yumei Zhou, Jan B Egan, Dan G Duda, Mitesh J Borad
Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect. Oncolytic virotherapy 6 (2017)

volume 6, 2016

Zeeshan Ahmad, Robert A Kratzke
Novel oncolytic viral therapies in patients with thoracic malignancies. Oncolytic virotherapy 6 (2016)

volume 5, 2016

Mingxu Guan, Yanping Ma, Sahil Rajesh Shah, Gaetano Romano
Thyroid malignant neoplasm-associated biomarkers as targets for oncolytic virotherapy. Oncolytic virotherapy 5 (2016)
Shilpa Bhatia, Samia M O'Bryan, Angel A Rivera, David T Curiel, J Michael Mathis
CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter. Oncolytic virotherapy 5 (2016)
Marlana Orloff
Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes. Oncolytic virotherapy 5 (2016)
K J Allan, David F Stojdl, S L Swift
High-throughput screening to enhance oncolytic virus immunotherapy. Oncolytic virotherapy 5 (2016)
Guy R Simpson, Kate Relph, Kevin Harrington, Alan Melcher, Hardev Pandha
Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances. Oncolytic virotherapy 5 (2016)
Veronica G Kinn, Valerie A Hilgenberg, Amy L MacNeill
Myxoma virus therapy for human embryonal rhabdomyosarcoma in a nude mouse model. Oncolytic virotherapy 5 (2016)
Katrina Sweeney, Gunnel Halldén
Oncolytic adenovirus-mediated therapy for prostate cancer. Oncolytic virotherapy 5 (2016)
Ahmed Majeed Al-Shammari, Huda Rameez, Maha F Al-Taee
Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy. Oncolytic virotherapy 5 (2016)
Alicia M Waters, Gregory K Friedman, Eric K Ring, Elizabeth A Beierle
Oncolytic virotherapy for pediatric malignancies: future prospects. Oncolytic virotherapy 5 (2016)
Michael J Burke
Oncolytic Seneca Valley Virus: past perspectives and future directions. Oncolytic virotherapy 5 (2016)

volume 4, 2015

Amy L MacNeill
On the potential of oncolytic virotherapy for the treatment of canine cancers. Oncolytic virotherapy 4 (2015)
Brian Hutzen, Corey Raffel, Adam W Studebaker
Advances in the design and development of oncolytic measles viruses. Oncolytic virotherapy 4 (2015)
Akshiv Malhotra, Arun Sendilnathan, Matthew O Old, Trisha M Wise-Draper
Oncolytic virotherapy for head and neck cancer: current research and future developments. Oncolytic virotherapy 4 (2015)
James J Cody, Douglas R Hurst
Promising oncolytic agents for metastatic breast cancer treatment. Oncolytic virotherapy 4 (2015)
Kotaro Saga, Yasufumi Kaneda
Oncolytic Sendai virus-based virotherapy for cancer: recent advances. Oncolytic virotherapy 4 (2015)
Nicolas Boisgerault, Carole Achard, Tiphaine Delaunay, Laurent Cellerin, Frédéric Tangy, Marc Grégoire, Jean-François Fonteneau
Oncolytic virotherapy for human malignant mesothelioma: recent advances. Oncolytic virotherapy 4 (2015)
Padma Sampath, Steve H Thorne
Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy. Oncolytic virotherapy 4 (2015)
Katherine M Dunlap, Mee Y Bartee, Eric Bartee
Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myeloma. Oncolytic virotherapy 4 (2015)
Jovian J Tsang, Harold L Atkins
The ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implications. Oncolytic virotherapy 4 (2015)
Boris Simovic, Scott R Walsh, Yonghong Wan
Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy. Oncolytic virotherapy 4 (2015)
Manuel Ramírez, Javier García-Castro, Gustavo J Melen, África González-Murillo, Lidia Franco-Luzón
Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technology. Oncolytic virotherapy 4 (2015)
Shay Tayeb, Zichria Zakay-Rones, Amos Panet
Therapeutic potential of oncolytic Newcastle disease virus: a critical review. Oncolytic virotherapy 4 (2015)
Caroline J Breitbach, John C Bell, Tae-Ho Hwang, David H Kirn, James Burke
The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594). Oncolytic virotherapy 4 (2015)
Thomas R Whisenhunt, Kiran F Rajneesh, James R Hackney, James M Markert
Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy. Oncolytic virotherapy 4 (2015)

Oncolytic virotherapy

Keyphrases

Publications

volume 10, 2021

volume 9, 2020

volume 8, 2019

volume 7, 2018

volume 6, 2017

volume 6, 2016

volume 5, 2016

volume 4, 2015